Dr. Reddys Q3 FY10 Press Meet Presentation

Q3 FY10 Results Update January 20, 2010

Safe Harbor Statement ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Consolidated Key Financial Highlights ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Impairment of Goodwill and Intangibles at betapharm in Germany Dec 09 Carrying Value before impairment Intangibles  €60 mn ‘ beta’ Brand  €66 mn Goodwill  €76 mn Non cash impairment (hit to P&L) Intangibles  €21 mn ‘ beta’ Brand  €12 mn Goodwill  €76 mn Dec 09 Carrying Value after impairment Intangibles  €39 mn ‘ beta’ Brand  €54 mn Goodwill  Nil ,[object Object],[object Object],[object Object]

Segmental Analysis : Revenues Global Generics Q3 Revenues at Rs. 1,172 crs

Global Generics : North America Product Pipeline : ANDAs Cumulative  141 Pending approvals  62 Para IVs  35 FTFs  13 Rs. Crs. ,[object Object],[object Object],[object Object],[object Object],Sumatriptan Base business

Global Generics : India ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Rs. Crs. ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Global Generics : Germany Rs. Crs. ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Global Generics : Russia Rs. Crs. ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Pharmaceutical Services & Active Ingredients Rs. Crs. ,[object Object],[object Object],[object Object],[object Object],DMFs Pipeline : Cumulative  388 US  146 Europe  116 Canada  58 RoW  68

Key Updates ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

P&L  Q3 FY10 All figures in Rs. Crs. except EPS Revenue Gross Profit % to sales SG&A % to sales R&D % to sales EBITDA % to sales Adjusted PAT % to sales Adjusted EPS Q3 FY10 Q3 FY09 Gr% 1,730 1,840 -6% 881 1,027 -14% 51% 56% 543 538 1% 31% 29% 89 103 -13% 5% 6% 367 419 -13% 21% 23% 231 260 -11% 13% 14% 13.6 15.4 -12%

Key Balance Sheet Items  Dec 09 Rs. Crs. Cash & Cash Equivalents Trade & Other receivables Inventories Property, plant & equipment Loans & borrowings (current & non current) Trade accounts payable Dec 09 Sep 09 554 615 1,161 1,316 1,291 1,314 2,141 2,128 1,252 1,452 591 720

Dr. Reddys Q3 FY10 Press Meet Presentation

Recommandé

Recommandé

Contenu connexe

Tendances

Tendances (20)

En vedette

En vedette (10)

Similaire à Dr. Reddys Q3 FY10 Press Meet Presentation

Similaire à Dr. Reddys Q3 FY10 Press Meet Presentation (20)

Dernier

Dernier (20)

Dr. Reddys Q3 FY10 Press Meet Presentation